Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mechanisms in COPD: differences from asthma.

P J Barnes1

  • 1Department of Thoracic Medicine, National Heart and Lung Institute, London, UK. p.j.barnes@ic.ac.uk

Chest
|February 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucocorticoid resistance in asthma.

American journal of respiratory and critical care medicine·1995
Same author

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.

The Journal of experimental medicine·1995
Same author

Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.

Molecular pharmacology·1995
Same author

Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages.

The American journal of physiology·1995
Same author

Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction.

Thorax·1995
Same journal

A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy.

Chest·2026
Same journal

Independent Prognostic Contributions of Anti-Ro52 and Anti-MDA5 in Autoimmune-Associated Interstitial Lung Disease.

Chest·2026
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
Same journal

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
Same journal

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept.

Chest·2026
See all related articles

Chronic obstructive pulmonary disease (COPD) involves neutrophilic airway inflammation and lung destruction, unlike asthma's eosinophilic inflammation. Corticosteroids effectively treat asthma but not COPD progression.

Area of Science:

  • Pulmonology
  • Immunology
  • Cellular Biology

Background:

  • Asthma and Chronic Obstructive Pulmonary Disease (COPD) are distinct inflammatory airway diseases.
  • Asthma research has advanced significantly, while COPD mechanisms remain less understood.
  • Inflammatory pathways, cellular players, and therapeutic responses differ markedly between asthma and COPD.

Purpose of the Study:

  • To differentiate the underlying inflammatory processes in asthma and COPD.
  • To highlight the distinct cellular and molecular mechanisms driving each condition.
  • To compare the therapeutic responses, particularly to corticosteroids, in asthma versus COPD.

Main Methods:

  • Comparative analysis of inflammatory cell profiles in asthma and COPD.
  • Review of key inflammatory mediators and their effects in both diseases.

Related Experiment Videos

  • Evaluation of corticosteroid efficacy in modulating inflammation and disease progression.

    • Main Results:

    • Asthma exhibits eosinophilic airway inflammation, impacting airways but sparing lung parenchyma, linked to hyperresponsiveness.
    • COPD is characterized by neutrophilic airway inflammation and irreversible parenchymal destruction, causing airflow obstruction.
    • Corticosteroids effectively suppress eosinophilic inflammation in asthma but show minimal impact on COPD inflammation or progression.

    Conclusions:

    • COPD and asthma represent fundamentally different inflammatory lung diseases.
    • The neutrophilic inflammation and structural damage in COPD are not responsive to corticosteroids.
    • Understanding these differences is crucial for developing targeted COPD therapies.